Plecanatide Peptide: Trulance, GC-C Agonist Uses and Safety Limits
Plecanatide peptide guide covering uroguanylin-analog biology, the Trulance label, chronic idiopathic constipation and IBS-C evidence, dosing context and safety limits.
Plecanatide is a peptide drug with a very different evidence profile from research-market "gut health" peptides. It is a synthetic 16-amino acid analog of uroguanylin, a naturally occurring human intestinal hormone, and it is sold as the FDA-approved oral tablet Trulance. Unlike many compounds discussed in peptide circles, plecanatide has a published prescribing information document, randomized phase 3 trials and labeled indications.
The key is that plecanatide is a locally acting gut secretagogue, not a systemic hormone peptide. It is designed to work on the surface of the intestinal lining and is barely absorbed into the bloodstream. That single fact shapes its mechanism, its dosing and its safety story.
This guide is educational and not medical advice. Plecanatide is a prescription medicine. It should be started, monitored, changed or stopped only through qualified medical care.
For related gastrointestinal and peptide context, compare this guide with linaclotide, the closely related guanylate cyclase-C agonist, plus teduglutide and octreotide as other gut-active peptide drugs. Background on what peptides are and the peptide half-life guide helps explain why a barely absorbed peptide behaves so differently from an injected one.
Plecanatide At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic 16-amino acid analog of uroguanylin, sold as Trulance. |
| Drug class | Guanylate cyclase-C (GC-C) agonist, a locally acting gut secretagogue. |
| Approved uses | Chronic idiopathic constipation (CIC) and IBS with constipation (IBS-C) in adults, per the FDA label. |
| Route and dose | One 3 mg tablet by mouth once daily, per the Trulance prescribing information. |
| Absorption | Minimally absorbed with negligible systemic availability; a plasma half-life could not be calculated. |
| Main safety frame | Boxed warning for serious dehydration in young children; diarrhea is the most common adverse reaction. |
| Developer | Synergy Pharmaceuticals; Trulance assets later acquired by Bausch Health. |
How A Guanylate Cyclase-C Agonist Works
The gut lining carries a receptor called guanylate cyclase-C, or GC-C, on the luminal surface of intestinal epithelial cells. Native hormones uroguanylin and guanylin normally activate this receptor as part of fluid and electrolyte balance. Plecanatide is built to mimic uroguanylin.
According to the FDA prescribing information, plecanatide and its active metabolite bind GC-C and act locally on the luminal surface of the intestine. Activation of GC-C raises both intracellular and extracellular cyclic guanosine monophosphate, or cGMP. The rise in intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly by activating the cystic fibrosis transmembrane conductance regulator, or CFTR, ion channel. More fluid in the lumen means softer stool and faster transit, which is the therapeutic point in constipation disorders.
A frequently discussed design detail is pH sensitivity. Uroguanylin is most active in the slightly acidic environment of the proximal small intestine, and plecanatide was engineered to reproduce that uroguanylin-like, pH-dependent behavior. This is the structural feature most often used to distinguish it from linaclotide, which is modeled on guanylin and bacterial heat-stable enterotoxin. Whether this design produces a meaningfully different clinical experience is a fair question, and head-to-head outcome data are limited.
Approval Status And Indications
Plecanatide is approved, not investigational. The Trulance label lists an Initial U.S. Approval of 2017. Developer Synergy Pharmaceuticals announced FDA approval for chronic idiopathic constipation in January 2017, and a second approval for irritable bowel syndrome with constipation in adults in January 2018. After Synergy entered bankruptcy, Bausch Health acquired the Trulance assets, completing the transaction in 2019.
| Indication | What the label supports | Important limit |
|---|---|---|
| Chronic idiopathic constipation (CIC) | Adults, one 3 mg tablet once daily. | It treats a functional bowel disorder, not an undiagnosed cause of constipation. |
| IBS with constipation (IBS-C) | Adults, one 3 mg tablet once daily. | The benefit in trials was modest over placebo and symptom-specific. |
| Pediatric use | Not established and partly contraindicated. | Contraindicated under age 6 because of a serious dehydration risk. |
The approved dose deserves emphasis. Although phase 3 trials studied both 3 mg and 6 mg, the marketed product and the label specify a single 3 mg tablet once daily. Higher amounts are not an approved "stronger" option.
What The Evidence Shows, And Its Limits
Plecanatide's approval rests on randomized, double-blind, placebo-controlled phase 3 trials. In a phase 3 chronic idiopathic constipation trial of 1,394 patients, plecanatide produced significantly more durable complete spontaneous bowel movement (CSBM) responders than placebo, reported as roughly 21 percent at 3 mg and 19.5 percent at 6 mg versus about 10 percent for placebo. Mean weekly CSBM frequency also rose more on plecanatide than placebo. A second randomized CIC trial reported consistent efficacy and safety.
For IBS-C, two identical phase 3 trials randomized adults meeting Rome III criteria to placebo or plecanatide 3 mg or 6 mg for 12 weeks. The published results describe significant improvements in abdominal pain and constipation symptoms with high tolerability, and later integrated analyses pooled the two trials.
Read those numbers honestly. The response rates are meaningfully above placebo but are not dramatic in absolute terms, which is typical for functional bowel disorders. The endpoints are symptom-based composites, not cures, and trials ran for about 12 weeks. The relevant comparison for many patients is not plecanatide versus nothing but plecanatide versus other options, including linaclotide, lubiprostone, osmotic laxatives and fiber, and direct head-to-head superiority data are sparse. The data support a real but modest, symptom-level benefit in selected adults.
Pharmacokinetics And Half-Life
This is where plecanatide differs sharply from injectable peptides. The FDA label states that plecanatide is minimally absorbed, with negligible systemic availability after oral dosing. Concentrations of plecanatide and its active metabolite in plasma were below the limit of quantitation in most samples after a 3 mg dose, so standard parameters such as AUC, maximum concentration and half-life could not be calculated.
In other words, there is no meaningful circulating half-life to quote, because the drug largely stays in the gut and acts where it is swallowed. That is a feature, not a gap in the data. It is also why systemic, hormone-style effects are not the expected mechanism, and why claims of body-wide "regeneration" or "anti-aging" from plecanatide have no basis in its pharmacology. For the general concept, see the peptide half-life guide.
Safety Limits
Plecanatide's safety follows directly from its mechanism. By design it pulls fluid into the intestine, so the dominant risks are diarrhea and dehydration.
| Safety issue | Why it matters |
|---|---|
| Serious dehydration in children (boxed warning) | The label carries a boxed warning; in juvenile animal studies plecanatide caused fatal dehydration in some young mice. |
| Contraindicated under age 6 | Younger patients may express more intestinal GC-C and are at higher risk of severe diarrhea and dehydration. |
| Contraindicated in bowel obstruction | Use is contraindicated in known or suspected mechanical gastrointestinal obstruction. |
| Diarrhea | The most common adverse reaction, reported in roughly 5 percent of treated adults versus about 1 percent on placebo. |
| Severe diarrhea | The label advises stopping the drug and rehydrating if severe diarrhea occurs. |
| Pediatric 6 to under 18 years | Safety and effectiveness are not established; avoid in this group. |
Diarrhea typically begins within the first weeks of treatment. Because the entire therapeutic effect is increased intestinal secretion, the line between intended effect and adverse effect is thin, and dehydration is the outcome to watch in vulnerable patients.
How To Evaluate A Plecanatide Claim
Ask a few questions before trusting any plecanatide claim.
First, is the claim about an approved use? Plecanatide is approved only for chronic idiopathic constipation and IBS-C in adults. Claims about weight loss, gut "healing," microbiome repair or longevity are outside the label and the trial evidence.
Second, does the claim respect the dose? The approved product is a single 3 mg oral tablet once daily. Anyone describing escalating or injectable plecanatide is not describing the approved medicine.
Third, does the claim acknowledge that the drug is barely absorbed? A locally acting gut peptide cannot plausibly drive systemic, body-wide effects, so systemic benefit claims are a red flag.
Fourth, does it mention the safety frame, especially diarrhea, the boxed dehydration warning and the pediatric contraindication? A source that skips these is incomplete.
Finally, is it comparing plecanatide fairly to alternatives such as linaclotide and standard laxatives, rather than presenting it as a unique breakthrough?
Bottom Line
Plecanatide is a real, FDA-approved peptide medicine with a clear and narrow job. It is a uroguanylin-analog guanylate cyclase-C agonist that increases intestinal fluid secretion, and randomized phase 3 trials support a modest but genuine benefit for chronic idiopathic constipation and IBS with constipation in adults at a 3 mg once-daily oral dose.
The same mechanism sets its limits. Plecanatide is barely absorbed, so it is not a systemic hormone peptide and has no credible body-wide or anti-aging rationale. Its main risks are diarrhea and dehydration, it carries a boxed warning and contraindication in young children, and it should not be used in suspected bowel obstruction. It is a targeted prescription tool for specific constipation disorders, not a general wellness peptide.
References
U.S. Food and Drug Administration. TRULANCE (plecanatide) tablets label, 2018.
U.S. Food and Drug Administration. TRULANCE (plecanatide) tablets label with boxed warning, 2021.
Miner PB Jr, et al. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.
DeMicco M, et al. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.
Brenner DM, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
Rao SSC, et al. Plecanatide Improves Symptoms of IBS-C: Integrated Efficacy and Safety Analysis of Two Phase 3 Trials.
Shah ED, et al. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
Synergy Pharmaceuticals. FDA Approval of TRULANCE (Plecanatide) for IBS-C in Adults.
Drugs.com. Trulance (plecanatide) FDA Approval History.